As we observe Parkinson’s Awareness Month this April, it’s crucial to recognize the immense impact of this neurodegenerative disorder on American families. With over 1 million people affected and 60,000 new cases diagnosed annually, Parkinson’s is the fastest-growing neurological condition in the U.S., taking an incalculable toll on patients...
Read More
Researchers have developed a blood test that detects Parkinson’s disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens.
Read More
GlaxoSmithKline is committing up to $2.2 billion for potential drugs to treat Parkinson’s and Alzheimer’s as well as other diseases in a deal announced Friday with drug firm Alector.
Read More
Biomedical engineers at Duke University have used deep brain stimulation based on light to treat motor dysfunction in an animal model of Parkinson’s disease. Here are the details.
Read MoreDURHAM – Swiss-based Axovant Sciences, a Roivant spinout, licensed a gene-therapy deal with Oxford BioMedica worth $842 million Wednesday likely to boost work in Durham, where it conducts a significant amount of research and development. Axovant (Nasdaq:AXON) saw its shares soar 44 percent Wednesday after the deal was announced. The company saw it share price plummet from more than $20 each in late 2017 to just over $1 recently after it reported that its neuro-drug for Alzheimer’s posted negative Phase 3 trial results. Axovant has licensed the exclusive worldwide rights to develop and commercialize the gene-therapy for Parkinson’s Disease, OXB-102,...
Read More
